HLA-DRB1 Antibody (MHC II)

Flow Cytometry: 1-2ug/million cells in 0.1ml,Immunofluorescence: 2-4ug/ml,Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)

Optimal dilution of the HLA-DRB1 antibody should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

This mAb reacts with the beta-chain of HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. The SPM289 antibody recognizes a different epitope than the L243 monoclonal antibody, and these antibodies do not cross-block binding to each other's respective epitopes. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

Activated human peripheral blood mononuclear cells were used as the immunogen for the HLA-DRB1 antibody.

This HLA-DRB1 antibody is available for research use only.

Cell surface

Protein G affinity chromatography

Human

P01911